Cover Image
市場調查報告書

Northern Light Pharmaceuticals AB的產品平台分析

Northern Light Pharmaceuticals AB - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 319988
出版日期 內容資訊 英文 18 Pages
訂單完成後即時交付
價格
Back to Top
Northern Light Pharmaceuticals AB的產品平台分析 Northern Light Pharmaceuticals AB - Product Pipeline Review - 2014
出版日期: 2014年11月24日 內容資訊: 英文 18 Pages
簡介

Northern Light Pharmaceuticals AB是總公司在瑞典的醫藥研究開發企業。進行疼痛及神經系統疾病的前臨床及臨床開發、計劃管理、產業開發等。開發中產品有治療胰癌症患者的疼痛的趨化素抑制劑,老年癡呆症治療的分泌酶調節劑等。

本報告提供Northern Light Pharmaceuticals AB的治療藥開發平台的現狀及各開發階段比較分析、各藥物標靶、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

Northern Light Pharmaceuticals AB的基本資料

  • Northern Light Pharmaceuticals AB概要
  • 主要資訊
  • 企業資料

Northern Light Pharmaceuticals AB:R&D概要

  • 主要的治療範圍

Northern Light Pharmaceuticals AB:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Northern Light Pharmaceuticals AB:開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Northern Light Pharmaceuticals AB:藥物簡介

  • Small Molecule to Antagonize Chemokine Receptor for Cancer Pain
  • Small Molecule to Inhibit Prostaglandin E2 for Pain
  • Small Molecule to Inhibit Secretase for Alzheimer's Disease

Northern Light Pharmaceuticals AB:開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各作用機制

Northern Light Pharmaceuticals AB:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

目錄
Product Code: GMDHC06560CDB

Summary

Global Markets Direct's, 'Northern Light Pharmaceuticals AB - Product Pipeline Review - 2014', provides an overview of the Northern Light Pharmaceuticals AB's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Northern Light Pharmaceuticals AB's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Northern Light Pharmaceuticals AB including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Northern Light Pharmaceuticals AB's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Northern Light Pharmaceuticals AB's pipeline products

Reasons to buy

  • Evaluate Northern Light Pharmaceuticals AB's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Northern Light Pharmaceuticals AB in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Northern Light Pharmaceuticals AB's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Northern Light Pharmaceuticals AB and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Northern Light Pharmaceuticals AB
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Northern Light Pharmaceuticals AB and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Northern Light Pharmaceuticals AB Snapshot
    • Northern Light Pharmaceuticals AB Overview
    • Key Information
    • Key Facts
  • Northern Light Pharmaceuticals AB - Research and Development Overview
    • Key Therapeutic Areas
  • Northern Light Pharmaceuticals AB - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Northern Light Pharmaceuticals AB - Pipeline Products Glance
    • Northern Light Pharmaceuticals AB - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Northern Light Pharmaceuticals AB - Drug Profiles
    • Small Molecule to Antagonize Chemokine Receptor for Cancer Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Prostaglandin E2 for Pain
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Secretase for Alzheimer's Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Northern Light Pharmaceuticals AB - Pipeline Analysis
    • Northern Light Pharmaceuticals AB - Pipeline Products by Target
    • Northern Light Pharmaceuticals AB - Pipeline Products by Molecule Type
    • Northern Light Pharmaceuticals AB - Pipeline Products by Mechanism of Action
  • Northern Light Pharmaceuticals AB - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Northern Light Pharmaceuticals AB, Key Information
  • Northern Light Pharmaceuticals AB, Key Facts
  • Northern Light Pharmaceuticals AB - Pipeline by Indication, 2014
  • Northern Light Pharmaceuticals AB - Pipeline by Stage of Development, 2014
  • Northern Light Pharmaceuticals AB - Monotherapy Products in Pipeline, 2014
  • Northern Light Pharmaceuticals AB - Preclinical, 2014
  • Northern Light Pharmaceuticals AB - Pipeline by Target, 2014
  • Northern Light Pharmaceuticals AB - Pipeline by Molecule Type, 2014
  • Northern Light Pharmaceuticals AB - Pipeline Products by Mechanism of Action, 2014

List of Figures

  • Northern Light Pharmaceuticals AB - Pipeline by Top 10 Indication, 2014
  • Northern Light Pharmaceuticals AB - Pipeline by Top 10 Target, 2014
  • Northern Light Pharmaceuticals AB - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top